HNGEHealthcare · Health Information ServicesThe 16 Wall Street analysts covering Hinge Health, Inc. hold a median 12-month price target of $105 — +10.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 17 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Hinge Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Volatility (20): The share price moves around a lot.
Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HNGE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +10.9% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Sept 2026 | Stifel | Maintains | Buy | $96 → $115 |
| 11 Aug 2026 | Truist Securities | Maintains | Buy | $85 → $112 |
| 11 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 5 Aug 2026 | Barclays | Maintains | Overweight | $97 → $100 |
| 5 Aug 2026 | Barclays | Maintains | Overweight | — |
| 5 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 5 Aug 2026 | Citizens | Maintains | Market Outperform | $96 → $107 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $100 → $105 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 5 Aug 2026 | Needham | Maintains | Buy | — |
| 5 Aug 2026 | Needham | Maintains | Buy | $76 → $97 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | $75 → $110 |
| 5 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 5 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 5 Aug 2026 | Wells Fargo | Maintains | Overweight | $90 → $103 |
| 27 July 2026 | Citizens | Maintains | Market Outperform | $80 → $96 |
| 27 July 2026 | Citizens | Maintains | Market Outperform | — |
| 27 July 2026 | Stifel | Maintains | Buy | — |
| 27 July 2026 | Stifel | Maintains | Buy | $79 → $90 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HNGE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 17 Sept 2026, Hinge Health, Inc. returned +66.9% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 55% of US stocks
Cheaper than 14% of US stocks
Cheaper than 4% of US stocks
Cheaper than 3% of US stocks
Higher than 87% of US stocks
Higher than 75% of US stocks
Higher than 95% of US stocks
Higher than 78% of US stocks
Higher than 78% of US stocks
Higher than 88% of US stocks
Higher than 87% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Hinge Health, Inc. has a market value of $7.5B and an enterprise value of $7.1B.
Revenue in the twelve months to 30 June 2026: $720.1M. The latest quarter grew 53.0% year on year.
Net income over the same four quarters: $109.1M, a 15.1% net margin.
Diluted earnings per share, trailing twelve months: $1.28.
Free cash flow in the twelve months to 30 June 2026: $283.9M, after $6.2M of capital spending.
Trailing P/E: 11.5×; forward P/E: 30.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Hinge Health, Inc. employs 1,437 people — $501K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Hinge Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CNBC's Jim Cramer said investors are overly focused on AI data-center stocks and should look to other areas of the market, highlighting aerospace, fintech, health care, and energy stocks as compelling opportunities.
Why it matters — The mention of health care as an area of opportunity could draw investor attention to the sector where Hinge Health operates.
Hinge Health Director Kristina Leslie sold 1,200 shares of the company for $105,876, reducing her directly held position by 4% while retaining a multi-million dollar stake. The transaction involved only directly held shares, with no indirect holdings reported.
Why it matters — HNGE watchers would note insider selling activity as it can signal a director's view on the stock, though the relatively small reduction and retained large stake moderate its significance.
Hinge Health Inc. (HNGE) reported earnings 30 days ago, and its stock has risen 13.7% since that report. The article poses the question of whether the stock can continue its upward movement.
Why it matters — Hinge Health watchers would care because the piece examines the stock's post-earnings performance and its potential trajectory.
Baron Small Cap Fund reported its Q2 2026 portfolio activity, noting the fund rose 12.57% while trailing the Russell 2000 Growth Index, which gained 25.71%. The update highlighted Vertiv's strong results and Planet Fitness's weaker performance during the quarter.
Why it matters — Hinge Health watchers would care because the fund's portfolio activity may reflect its positioning and performance within the small-cap growth segment where Hinge Health operates.
Schaeffers Research published a list of 15 stocks with potential for short squeezes, noting that rising bond yields have put the broader stock market on edge. The report suggests that contrarian traders might keep short-squeeze candidates in mind given current market conditions.
Why it matters — HNGE watchers may learn whether the company is included among stocks considered short-squeeze candidates under current market conditions.
The 16 Wall Street analysts covering Hinge Health, Inc. have a median 12-month price target of $105, with estimates ranging from $85 to $140. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Hinge Health, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hinge Health, Inc. 79 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Sept 2026, Hinge Health, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +10.9% from the last close, and Ticker Nerd's factor model ranks Hinge Health, Inc. 79 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Hinge Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HNGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $140 over the next 12 months.
Hinge Health, Inc. returned +66.9% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Hinge Health, Inc. Class A Common Stock represents ownership in Hinge Health, a digital healthcare company focused on musculoskeletal care.
The most recent item we track (CNBC, 8 Sept 2026): "Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead". CNBC's Jim Cramer said investors are overly focused on AI data-center stocks and should look to other areas of the market, highlighting aerospace, fintech, health care, and energy stocks as compelling opportunities.
Hinge Health, Inc. Class A Common Stock represents ownership in Hinge Health, a digital healthcare company focused on musculoskeletal care. The company provides software-driven solutions for joint and muscle health, combining virtual care, clinician support, and digital programs designed to help people manage acute injury, chronic pain, and recovery from surgery. Its platform is used by employers, health plans, and other healthcare payers seeking scalable care delivery for members with MSK needs. Hinge Health also incorporates technologies such as artificial intelligence, motion tracking, and connected wearable devices to support personalized care experiences. Based in San Francisco, Hinge Health serves a specialized segment of the healthcare technology market centered on prevention, treatment, and management of musculoskeletal conditions.
CEO Mr. Daniel A. Perez · 1,437 employees · United States · https://www.hingehealth.com
